Thomas Smith
Stock Analyst at Leerink Partners
(1.34)
# 3,274
Out of 4,712 analysts
70
Total ratings
29.03%
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $3.36 | +167.86% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $2.73 | +156.41% | 7 | Nov 19, 2024 | |
| ALMS Alumis | Initiates: Outperform | $29 | $8.06 | +259.80% | 1 | Jul 23, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $19.79 | +97.07% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $4.94 | +426.32% | 1 | Mar 25, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Market Perform | $10 | $1.69 | +491.72% | 2 | Feb 21, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $7.12 | +180.90% | 1 | Nov 14, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $430 → $435 | $626.31 | -30.55% | 3 | Mar 3, 2023 | |
| IRON Disc Medicine | Initiates: Outperform | $36 | $64.12 | -43.86% | 1 | Feb 28, 2023 | |
| EQ Equillium | Maintains: Outperform | $12 → $7 | $0.69 | +908.65% | 3 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $1.14 | +514.04% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $24.49 | -14.25% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $19.45 | +131.36% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $4.27 | +40.52% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $6.82 | -12.02% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $1.03 | +385.44% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $55.37 | -69.30% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $25.39 | +152.07% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $19.51 | +258.79% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $29 | $7.88 | +268.02% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $4.35 | +497.70% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $13 → $12 | $1.30 | +823.08% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $41.16 | -70.85% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $3.70 | +170.27% | 4 | Apr 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $5.15 | +7,666.99% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $16.42 | +387.21% | 2 | Dec 8, 2020 |
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $3.36
Upside: +167.86%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $2.73
Upside: +156.41%
Alumis
Jul 23, 2024
Initiates: Outperform
Price Target: $29
Current: $8.06
Upside: +259.80%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $19.79
Upside: +97.07%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $4.94
Upside: +426.32%
RAPT Therapeutics
Feb 21, 2024
Downgrades: Market Perform
Price Target: $10
Current: $1.69
Upside: +491.72%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $7.12
Upside: +180.90%
argenx SE
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $626.31
Upside: -30.55%
Disc Medicine
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $64.12
Upside: -43.86%
Equillium
Feb 8, 2023
Maintains: Outperform
Price Target: $12 → $7
Current: $0.69
Upside: +908.65%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $1.14
Upside: +514.04%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $24.49
Upside: -14.25%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $19.45
Upside: +131.36%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $4.27
Upside: +40.52%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $6.82
Upside: -12.02%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $1.03
Upside: +385.44%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $55.37
Upside: -69.30%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $25.39
Upside: +152.07%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $19.51
Upside: +258.79%
Jul 11, 2022
Maintains: Outperform
Price Target: $50 → $29
Current: $7.88
Upside: +268.02%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $4.35
Upside: +497.70%
May 12, 2022
Maintains: Market Perform
Price Target: $13 → $12
Current: $1.30
Upside: +823.08%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $41.16
Upside: -70.85%
Apr 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $3.70
Upside: +170.27%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $5.15
Upside: +7,666.99%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $16.42
Upside: +387.21%